Table 2 Grade 3 or 4 Adverse Events

Adverse Events	IP/IV arm (N = 106)^a	IV arm (N = 107)^b	P value^c
No. (%)
Leukopenia	57 (53.8)	38 (35.2)	0.006
Neutropenia	70 (66.0)	64 (59.3)	0.305
anaemia	25 (23.6)	6 (5.6)	<0.001
Platelet count < 50*10^9	13 (12.3)	8 (7.5)	0.241
Gastrointestinal event	11 (10.4)	2 (1.9)	0.010
Infection	12 (11.3)	5 (4.7)	0.073
Thromboembolic event (Grade 5)	1 (0.9)^d	0 (0)	0.498

^a 3 patients in IP group did not receive IV chemotherapy.
^b 1 patients did not receive any protocol-based therapy. 1 patient only received 3 cycles of IV therapy after cytoreduction and the data of adverse events were missed.
^cP values were calculated by χ²-test (grades 0, 1, and 2 vs. grades 3 and 4).
^d 1 patient died of mesenteric venous thrombosis after completing 4 cycles of IP therapy and 4 cycles of IV therapy. In the intraperitoneal chemotherapy group, other 3 patients encountered grade 2 thromboembolic events (deep venous thrombosis of the lower extremities). And in the intravenous chemotherapy group, 1 patient encountered a grade 2 thromboembolic event (Upper-extremity deep vein thrombosis), which was PICC line-associated thrombosis³¹

Quick links

Search